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Increased Infection Risk in Addison’s Disease and 
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A Primary Care Database Cohort Study
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ORCiD numbers: 0000-0001-5106-9719 (W. Arlt).
Context:  Mortality and infection-related hospital admissions are increased in patients with 
primary adrenal insufficiency (PAI). However, the risk of primary care–managed infections in 
patients with PAI is unknown. 
Objective:  To estimate infection risk in PAI due to Addison’s disease (AD) and congenital 
adrenal hyperplasia (CAH) in a primary care setting. 
Design:  Retrospective cohort study using UK data collected from 1995 to 2018. 
Main outcome measures:  Incidence of lower respiratory tract infections (LRTIs), urinary tract 
infections (UTIs), gastrointestinal infections (GIIs), and prescription counts of antimicrobials in 
adult PAI patients compared to unexposed controls. 
Results:  A diagnosis of PAI was established in 1580 AD patients (mean age 51.7 years) and 602 
CAH patients (mean age 35.4 years). All AD patients and 42% of CAH patients were prescribed 
glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%). 
AD and CAH patients exposed to glucocorticoids, but not CAH patients without glucocorticoid 
treatment, had a significantly increased risk of LRTIs (adjusted incidence rate ratio AD 2.11 [95% 
confidence interval (CI) 1.64–2.69], CAH 3.23 [95% CI 1.21–8.61]), UTIs (AD 1.51 [95% CI 1.29–1.77], 
CAH 2.20 [95% CI 1.43–3.34]), and GIIs (AD 3.80 [95% CI 2.99–4.84], CAH 1.93 [95% CI 1.06–3.52]). 
This was mirrored by increased prescription of antibiotics (AD 1.73 [95% CI 1.69–1.77], CAH 1.77 
[95% CI 1.66–1.89]) and antifungals (AD 1.89 [95% CI 1.74–2.05], CAH 1.91 [95% CI 1.50–2.43]). 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits un-
restricted reuse, distribution, and reproduction in any medium, provided the original 
work is properly cited.
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Conclusions:  There is an increased risk of infections and antimicrobial use in PAI in the primary 
care setting at least partially linked to glucocorticoid treatment. Future studies will need to 
address whether more physiological glucocorticoid replacement modes could reduce this risk.
P rimary adrenal insufficiency (PAI) is a severe and potentially life-threatening condition caused by the 
failure of the adrenal cortex to produce glucocorticoids 
and, in most cases, mineralocorticoids, which occurs in 
the setting of adrenal disease (1). The 2 most frequent 
causes of PAI are autoimmune adrenalitis, the most fre-
quent cause of Addison’s disease (AD) in Western coun-
tries, and congenital adrenal hyperplasia (CAH).
The prognosis of patients with PAI has improved 
considerably after life-saving glucocorticoid replace-
ment therapy became available in the 1950s; however, 
an increased risk of death has been described in both 
AD and CAH patients even in recent years (2, 3). In pa-
tients with AD, this has been attributed to adrenal crisis- 
and infection-related mortality (4), while for both CAH 
and AD patients an increased cardiovascular-related 
mortality has been described (3, 4). Other studies have 
reported an increased use of antimicrobial agents and 
infection-related hospital admissions in patients with 
PAI (5, 6). Recent evidence suggests that the increased 
risk of infections in these patients could be explained by 
an impairment of natural killer cell function (7), which 
may be caused by the nonphysiological delivery of 
glucocorticoids by currently available preparations and 
an associated change in clock gene expression patterns 
in immune cells (7, 8).
No studies have estimated yet the overall risk of 
common infections in people with PAI, namely, infec-
tions that are primarily managed in the primary care 
setting and usually do not require hospital admission. 
However, such infections potentially expose PAI pa-
tients to significant risk of adrenal crisis. Therefore, this 
study aimed to assess the risk of common types of pri-
mary care–managed infections—namely, lower respira-
tory tract infections (LRTIs), urinary tract infections 
(UTIs), and gastrointestinal infections (GIIs)—and the 
use of antimicrobials in the primary care setting in pa-
tients with PAI, including both AD and CAH patients 
with and without glucocorticoid therapy.
Materials and Methods
Study design and setting
We conducted a population-based, retrospective, open co-
hort study to determine the infection risk of patients with AD 
and CAH in the primary care setting. We assessed the risk of 
LRTIs, UTIs, and GIIs and the counts of antimicrobial pre-
scriptions. We used data from The Health Improvement 
Network (THIN) database, comprising anonymized electronic 
medical records from UK general practitioner (GP) practices 
covering over 5% of the UK population. THIN holds data on 
demographic characteristics, clinical diagnoses, physical meas-
urements, laboratory results and drug prescriptions recorded 
using a clinical Read code system. Patients registered in THIN 
have similar age and sex distributions to the general UK popu-
lation, and, therefore, THIN data are well suited for epidemio-
logical studies (9, 10).
Study population and period
Our study population consisted of 2  “exposed” cohorts, 
comprising adult patients (≥18 years old) diagnosed with AD 
or CAH according to selected Read codes (11, 12). (see sup-
plementary materials (13)) We excluded patients who were 
at any time point coded with a code consistent with other 
causes of adrenal insufficiency. We could not retrieve data on 
21-hydroxylase autoantibodies in the study participants, due 
to the nature of the study. Therefore, in this paper, we defined 
AD as PAI not caused by CAH. To ensure accuracy of case def-
inition in the AD cohort, we only included patients who had at 
least 1 prescription of both glucocorticoids (accepting gluco-
corticoids commonly used in AD) and mineralocorticoids. We 
also performed a sensitivity analysis to include only patients 
who had at least 2 prescription of both glucocorticoids and 
mineralocorticoids. We subdivided the CAH cohort in two 
subcohorts: (i) patients who had at least 1 glucocorticoid pre-
scription at any point (using the same glucocorticoid codes 
used for AD patients) and (ii) patients who were never pre-
scribed with any glucocorticoid therapy, since patients with 
CAH do not always require glucocorticoid therapy. For every 
exposed patient, we randomly selected 2 individuals from a 
pool of patients matched for age, sex, and GP practice who did 
not have a Read code consistent with PAI at any point before 
or during the observation period.
The study period extended from January 1, 1995 to January 
1, 2018. Patients were eligible for inclusion 1 year from the 
latest of the following dates: study start date, patient registra-
tion date with the GP practice, and practice eligibility date (the 
date when practices have implemented an electronic medical 
record and have passed the assessment for acceptable data 
quality). The 1-year lag period was applied to ensure there was 
enough time to document all information accurately after regis-
tration with the practice or after a practice was deemed eligible 
to take part. To ensure acceptable data quality, practices were 
required to have used the electronical health record system for 
at least 1 year and have acceptable mortality reporting (13).
The index date (ie, the date when follow-up commences) 
was defined as the date of diagnosis for newly diagnosed pa-
tients or, if they were already diagnosed with PAI, the date 
when they registered with an eligible GP practice. Patients 
were followed from index date up until the earliest of the 
following dates: outcome of interest (only for estimating the 
incidence of infections), patient transfer date from practice, 
patient death, practice’s last data collection date, and study 
end date.
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Outcomes
For the first outcome, the incidence of infections, we used 
the Read codes that identify cases of LRTIs, UTIs and GIIs 
(see supplementary materials (13)). These infections were 
chosen because they are the most common type of infections 
evidenced in general population and they are frequently diag-
nosed in primary care (14). We then calculated the occurrence 
of this outcome in the different cohorts.
For the second outcome, antimicrobial use, we used the 
codes for antibiotics and antifungals as classified in the British 
National Formulary. We then calculated the total number of 
prescriptions for every antimicrobial in each cohort.
For each of the study groups, we analyzed age, sex, body 
mass index (BMI), smoking status, Townsend Deprivation 
Index (a measure of deprivation within a population) (15), 
Charlson Comorbidity Index (a method of classifying 
comorbidities to predict mortality in primary care) (16, 
17), and type of glucocorticoids prescribed at baseline. For 
the AD cohort (in which most patients were likely to have 
autoimmune PAI), given the frequent association with other 
autoimmune conditions, we also evaluated the prevalence of 
associated autoimmune comorbidities.
Statistical analysis
Descriptive statistics were used to summarize the base-
line characteristics for the exposed and unexposed groups of 
patients. Categorical variables were investigated using Chi-
square test and continuous variables were analyzed using a 
t test.
Adjusted incidence rate ratios (aIRRs) for specific infec-
tions and antimicrobial prescriptions were calculated after 
adjustment for age, sex, smoking status, BMI, Townsend 
Deprivation Index, and Charlson Comorbidity Index, using 
multivariate Poisson regression analysis. Statistical analyses 
were conducted using Stata version 14.2 (Stata Corp, College 
Station, Texas, US) and GraphPad Prism 7.04 (GraphPad 
Software Inc, San Diego, California, US).
Ethical approval
The THIN database obtained ethical approval from the 
South East Multicentre Research Ethics Committee in 2003. 
The present study was reviewed and approved (study refer-
ence: 18THIN063) by the THIN Scientific Review Committee 
in July 2018.
Results
Baseline characteristics of the AD cohort
In total, 1 580 patients fulfilled the AD criteria; these 
were matched with 3 158 unexposed individuals (Table 
1). The mean age of AD patients was 51.7 years, and 
the majority were women (57.8%). Compared to un-
exposed individuals, AD patients had a lower median 
BMI, while the Townsend Deprivation Index did not 
differ significantly between the 2 groups. The Charlson 
Comorbidity Index showed that AD patients had an 
increased burden of comorbidities compared to the 
matched population; this included a higher prevalence 
of autoimmune comorbidities, including autoimmune 
thyroid diseases, type 1 diabetes mellitus (T1DM), ul-
cerative colitis, celiac disease, and pernicious anemia 
(Table 1).
Baseline characteristics of the CAH cohort
In total, 602 patients fulfilled the CAH criteria and 
were subdivided into 254 glucocorticoid-treated pa-
tients (42.2%) and 348 patients not on glucocorticoids 
(57.8%). These were matched with 508 and 696 unex-
posed controls, respectively (Table 2).
The majority of CAH patients were female (72.3%), 
with a lower mean age in glucocorticoid-treated patients 
at cohort entry (33.4 vs. 36.9 years). CAH patients had 
a higher median BMI compared to controls, and this 
was evident for both glucocorticoid-treated subcohort 
and the CAH subcohort never treated with glucocortic-
oids. CAH patients were more frequently overweight 
or obese (60.3% vs. 44.2% in matched controls, P ˂ 
0.001), and this was observed both in glucocorticoid-
treated and untreated CAH patients (59.1 and 61.1%, 
respectively). The Townsend Deprivation Index and the 
Charlson Comorbidity Index did not differ between 
CAH patients and controls.
Glucocorticoid prescriptions
The most commonly prescribed type of glucocorticoid 
in the AD cohort was hydrocortisone (1  296 pa-
tients, 82%), followed by prednisolone (187 patients, 
11.8%). Only a minority of patients were prescribed 
cortisone acetate (91 patients, 5.8%, no longer avail-
able in the United Kingdom) and dexamethasone (6 
patients, 0.4%).
In the glucocorticoid-treated CAH cohort, prednis-
olone was most commonly prescribed (127 patients, 
50.0%), followed by hydrocortisone (96 patients, 
37.8%), with a small minority receiving dexametha-
sone (15 patients, 5.9%) or cortisone acetate (11 
patients, 4.3%). Only 5 CAH patients (2%) were 
prescribed a combination of short- and long-acting 
glucocorticoids.
Risk of infections
The risk of LRTIs, UTIs, and GIIs was significantly 
increased in the AD cohort compared to unexposed 
patients, with the highest relative risk observed for 
GIIs (aIRR 3.80 [95% CI 2.99–4.84]) followed by 
LRTIs (aIRR 2.11 [95% CI 1.64–2.69]) and UTIs 
(aIRR 1.51 [95% CI 1.29–1.77]) (Table 3; Fig. 1). 
These results were confirmed in the subanalysis of pa-
tients who had at least 2 prescriptions of both gluco-
corticoids and mineralocorticoids (94.5% of the total 
cohort (see supplementary materials (13)).
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In the overall CAH cohort, there was a significantly 
increased risk of UTIs and LRTIs (aIRR 1.40 [95% 
CI 1.06–1.85] and 2.36 [95% CI 1.25–4.42], respect-
ively), with no difference in gastrointestinal infections 
(Table 4; Fig. 1). However, when analyzing the popu-
lation accordingly to glucocorticoid use, only patients 
exposed to glucocorticoids had an increased risk of in-
fections, with the highest risk observed for LRTIs (aIRR 
3.23 [95% CI 1.21–8.61]) followed by UTIs (aIRR 
2.20 [95% CI 1.43–3.4]) and GIIs (aIRR 1.93 [95% 
CI 1.06–3.52]) (Table 4; Fig. 1). In contrast, infection 
risk in CAH patients not treated with glucocorticoids 
did not differ from that observed in the matched back-
ground population.
Antimicrobial prescriptions
Prescription rates of antibiotics and antifungals were 
increased in patients with AD (aIRR 1.73 [95% CI 
1.69–1.77] and 1.89 [95% CI 1.74–2.05], respectively) 
(Table 5; Fig. 1). These results were confirmed in the 
subanalysis of patients who had at least 2 prescriptions 
of both glucocorticoids and mineralocorticoids (see sup-
plementary materials (13)).
Similarly, we observed increased antimicrobial pre-
scription rates in CAH patients, with a higher prescrip-
tion rate in glucocorticoid-treated patients (antibiotics: 
aIRR 1.77 [95% CI 1.66–1.89]; antifungals: aIRR 1.91 
[95% CI 1.50–2.43]) than in CAH patients not ex-
posed to glucocorticoids (antibiotics: aIRR 1.15 [95% 
CI 1.08–1.23]; antifungals: aIRR 1.44 [95% CI 1.18–
1.83]) (Table 6; Fig. 1).
Given the higher incidence of T1DM in our AD 
cohort (8% vs. 0.5% in matched controls) and given 
the potentially higher risk of infections in T1DM pa-
tients, we performed a subgroup analysis comparing 
AD patients with and without T1DM to a matched un-
exposed cohort. Findings were similar, although given 
the smaller number of T1DM patients group, some did 
Table 1. Baseline Characteristics of Patients With AD and Matched Unexposed Patients
AD Patients (n = 1580) Matched Unexposed Patients (n = 3158)
Age years, mean ± SD 51.7 ± 18.5 51.7 ± 18.5
Male sex, n (%) 666 (42.2) 1.330 (42.1)
BMI, total N 1227 2264
 median (interquartile range) 24.3 (21.5–27.6)a 25.5 (22.6–28.9)
 ˂18.5 kg/m2, n (%) 87 (7.1) 51 (2.3)
 18.5–25 kg/m2, n (%) 606 (49.4) 973 (43.0)
 25–30 kg/m2, n (%) 362 (29.5) 791 (34.9)
 ≥30 kg/m2, n (%) 172 (14.0) 449 (19.8)
 Missing, n 353 894
Smoking status, total N 1384 2679
 Nonsmoker, n (%) 882 (63.7)a 1548 (57.8)
 Ex-smoker, n (%) 250 (18.1) 490 (18.3)
 Smoker, n (%) 252 (18.2)a 641 (23.9)
 Missing, n 196 479
Townsend Deprivation Index, total N 1373 2780
 1 (least deprived), n (%) 350 (25.5) 743 (26.7)
 2, n (%) 306 (22.3) 590 (21.2)
 3, n (%) 290 (21.1) 607 (21.8)
 4, n (%) 255 (18.6) 471 (16.9)
 5 (most deprived), n (%) 172 (12.5) 369 (13.3)
 Missing, n 207 378
Charlson Comorbidity Index   
 0 (no comorbidities), n (%) 863 (54.6)a 2263 (71.7)
 1, n (%) 377 (23.9)a 536 (17.0)
 ≥2 (more comorbidities), n (%) 340 (21.5)a 359 (11.4)
Associated autoimmune comorbidities
 Hyperthyroidism, n (%) 40 (2.5)a 16 (0.5)
 Hypothyroidism, n (%) 457 (28.9)a 122 (3.9)
 Rheumatoid arthritis, n (%) 25 (1.6) 37 (1.2)
 Type 1 diabetes mellitus, n (%) 127 (8.0)a 15 (0.5)
 Inflammatory bowel disease, n (%) 29 (1.8)a 22 (0.7)
 Crohn’s disease, n (%) 9 (0.6) 9 (0.3)
 Ulcerative colitis, n (%) 20 (1.3)a 11 (0.4)
 Coeliac disease, n (%) 25 (1.6)a 10 (0.3)
 Multiple sclerosis, n (%) <5 8 (0.3)
 Pernicious anaemia, n (%) 41 (2.6)a 15 (0.5)
 Systemic lupus erythematosus, n (%) 6 (0.4) n  <  5
aP < 0.05 for AD patients vs. unexposed cohort.
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not reach statistical significance (see supplementary 
materials (13)).
Discussion
In this population-based study we found that the risk 
of three common infections (LRTIs, UTIs, and GIIs) 
was increased in the primary care setting in patients 
with PAI, as compared to population-based matched 
controls. This was also supported by our finding of in-
creased prescription rates of antimicrobials in in pa-
tients with PAI. Moreover, we found that CAH patients 
not receiving glucocorticoids did not have an increased 
risk of infections, indicating that glucocorticoid therapy 
might at least partly drive the increased infection risk 
observed in PAI. To our knowledge, our study is the first 
to analyze the risk of infection in PAI according to dif-
ferent etiologies and also the first to evaluate these out-
comes in a primary care setting.
Previous studies have described an increased 
infection-related mortality in patients with AD (2, 4), 
but not in CAH patients (3). This was attributed to in-
fections representing a possible trigger for a fatal ad-
renal crisis. Smans and colleagues (5) reported an 
increase of the use of antimicrobials and of infection-
related hospital admissions in PAI; however, the authors 
focused on hospital-treated infections only, possibly 
overestimating the actual incidence of this complication 
due to a lower threshold for admission in PAI patients. 
In addition, information on the actual etiology of PAI 
was not available in this study, as PAI was diagnosed 
based on concomitant glucocorticoid and mineralocor-
ticoid prescriptions, which did not allow for the differ-
entiation between AD, CAH, and other causes of PAI.
Until recently, it was unclear whether the observed 
increase in infection episodes in patients with PAI 
is related to the underlying disease itself or to the 
nonphysiological delivery of glucocorticoid replace-
ment by currently available glucocorticoid prepar-
ations. Autoimmune AD patients frequently also suffer 
from other autoimmune comorbidities (18), and this 
was confirmed in our study, with more prevalent auto-
immune disease in our AD cohort, which can be safely 
assumed to consist of a large majority of patients with 
AD of autoimmune origin. However, in CAH patients, 
there is only marginal evidence of an imbalance of im-
mune function (19), and as we found similar increases 
in infection risk in the CAH cohort, potential etiology-
related immune function is unlikely to explain the in-
creased susceptibility to infections we observed.
Supraphysiological glucocorticoid doses, as usu-
ally administered in the context of chronic inflam-
matory disease, is well known to cause changes in 
the immune system, with consequently increased risk 
Table 3. Absolute and relative risk of infections in AD patients and matched cohort
AD Cohort (n = 1580) Matched Unexposed Cohort (n = 3158)
Lower respiratory tract infections
 Outcome events, n (%) 130 (8.2) 137 (4.3)
 Person-years, n 10 337 22 836
 Crude incidence rate/1000-person years 12.58 6.00
 Follow-up years, median (interquartile range) 4.87 (1.78–10.20) 5.78 (2.37–11.12)
 Unadjusted incidence rate ratio (95% CI) 2.10 (1.65–2.66)
  P-value 0.001
 Adjusted incidence rate ratio (95% CI)a 2.11 (1.64–2.69)
  P-value 0.001
Urinary tract infections
 Outcome events, n (%) 282 (17.9) 396 (12.5)
 Person-years, n 9 248 21 003
 Crude incidence rate/1000-person years 30.49 18.85
 Follow-up years, median (interquartile range) 4.09 (1.44–9.14) 5.08 (2.11–10.26)
 Unadjusted incidence rate ratio (95% CI) 1.62 (1.39–1.88)
  P-value 0.001
 Adjusted incidence rate ratio (95% CI)a 1.51 (1.29–1.77)
  P-value 0.001
Gastro-intestinal infections
 Outcome events, n (%) 194 (12.3) 110 (3.5)
 Person-years, n 9 598 22 662
 Crude incidence rate/1000-person years 20.21 4.85
 Follow-up years, median (interquartile range) 4.49 (1.67–9.31) 5.63 (2.37–11.03)
 Unadjusted incidence rate ratio (95% CI) 4.16 (3.30–5.26)
  P-value 0.001
 Adjusted incidence rate ratio (95% CI)a 3.80 (2.99–4.84)
  P-value 0.001
aAdjusted for age, gender, smoking status, BMI, Townsend Deprivation Index and Charlson Comorbidity Index.
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of bacterial and fungal infections (20). However, this 
has not been demonstrated for the physiological re-
placement doses generally used in patients with PAI. 
Still, currently available glucocorticoid replacement 
therapy does not provide a physiological substitution, 
with significant peaks and troughs of cortisol avail-
ability during the day following oral intake of imme-
diate release glucocorticoid preparations. In addition, 
significant heterogeneity exists in the management of 
glucocorticoid replacement in clinical practice; a re-
cent paper recorded 25 different regimens with which 
glucocorticoid therapy is administered in AD pa-
tients receiving a daily hydrocortisone of 20 mg (21). 
Therefore, it would come as no surprise that physio-
logical dose glucocorticoid therapy is not free of side 
effects, if administered in a nonphysiological delivery 
pattern. An improvement in metabolic outcomes after 
switching from standard cortisol replacement to more 
Figure 1. Forest plot of outcomes. Panel A: Adjusted incidence rate ratio (aIRR) for infections and antimicrobial prescriptions in Addison’s disease 
(AD) and congenital adrenal hyperplasia (CAH) cohorts. Panel B: aIRR for infections and antimicrobial prescriptions in CAH patients separately for 
patients with and without chronic glucocorticoid treatment.
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physiological cortisol replacement via continuous 
subcutaneous hydrocortisone was previously demon-
strated in both AD and CAH patients (22, 23).
Some recent papers have indeed suggested that ad-
verse changes in immune function might occur with 
glucocorticoid replacement in PAI. A  recent paper 
documented significantly decreased natural killer cyto-
toxicity in patients with PAI (7), which was present in 
both patients with autoimmune adrenalitis and those 
with PAI following bilateral adrenalectomy, indicating 
that the underlying etiology did not play a role in these 
changes in immune function. A recent randomized con-
trol trial including patients with primary and secondary 
adrenal insufficiency reported a reduction in respiratory 
tract infections with modified-release hydrocortisone 
(8). However, this was a secondary outcome, based on 
self-reported questionnaires on infections and not veri-
fied against medical records, thereby providing only 
limited evidence. A  study on immune function in the 
same cohort reported dysregulation of circadian gene 
expression in peripheral blood mononuclear cells in 
the PAI patients at baseline, which attenuated after the 
switch to modified-release hydrocortisone therapy (24). 
The findings of our study, including both patients with 
AD and CAH, suggest that exogenous glucocorticoid is 
at least a contributory factor to the increased infection 
risk we observed, given that no significant increase in 
infection risk was observed in the CAH patients not re-
ceiving glucocorticoid therapy.
Both our AD and CAH populations had increased 
prescription rates for antibiotics and antifungals. 
Interestingly, increased prescription rates were also 
noted in the CAH patients not receiving glucocorticoid 
treatment, albeit to a much lower extent. This could 
possibly be explained by a lower threshold for pre-
scribing antimicrobials due to the perceived risk of 
adrenal crisis in CAH patients; in fact, up to 60% of 
nonclassic CAH patients, who usually do not receive 
chronic glucocorticoid replacement, have been reported 
to have at least partial glucocorticoid deficiency as as-
sessed by cosyntropin testing (25).
The highest increase in risk of infection in our AD 
cohort was seen in GIIs, while for the CAH cohort on 
glucocorticoids the most significant increase in risk was 
seen in LRTIs and UTIs; however, the differences be-
tween the 3 infection groups was not statistically sig-
nificant. This may be explained by the age difference 
between AD and CAH patients, with mean ages of 51.7 
and 35.4 years, respectively. Indeed, LRTIs and UTIs are 
more frequently diagnosed in older patients (26, 27), 
and this was noted in our matched populations as well 
(population matched for AD: LRTIs 4.3%, UTIs 12.5%; 
population matched for CAH patients on glucocortic-
oids: LRTIs 1.4%, UTIs 8.5%). Therefore, the higher 
aIRR of LRTIs and UTIs in CAH patients is probably 
related to a difference in age-related background risk.
Our AD cohort had an age and sex distribution 
similar to the one reported in other papers (2, 5), and 
the types of prescribed glucocorticoid preparations at 
baseline in this cohort were not different from the ones 
reported in a recent worldwide survey (28). Our CAH 
cohort was younger that the AD cohort, consistent with 
the different etiology of these 2 diseases, and the types of 
glucocorticoids prescribed was similar to those reported 
Table 5. Antimicrobial Prescriptions Counts in AD Patients Compared to the Matched Control Cohort
 AD Cohort (n = 1580)
Matched Unexposed  
Cohort (n = 3158)
Antibiotic prescriptions
 Count of prescriptions, n 13 286 15 884
 Person-years, n 10 767 23 308
 Count rates (per 1000 years) 1234 681
 Follow-up years, median (interquartile range) 5.12 (1.95–10.77) 5.90 (2.54–11.33)
 Unadjusted incidence rate ratio (95% CI) 1.81 (1.77–1.85)
  P-value 0.001
 Adjusted incidence rate ratio (95% CI)a 1.73 (1.69–1.77)
  P-value 0.001
Antifungal prescriptions
 Count of prescriptions, n 1191 1213
 Person-years, n 10 767 23 308
 Count rates (per 1000 years) 111 52
 Follow-up years, median (interquartile range) 5.12 (1.95–10.77) 5.90 (2.54–11.33)
 Unadjusted incidence rate ratio (95% CI) 2.13 (1.96–2.30)
  P-value 0.001
 Adjusted incidence rate ratio (95% CI)a 1.89 (1.74–2.05)
  P-value 0.001
aAdjusted for age, gender, smoking status, BMI, Townsend Deprivation Index and Charlson Comorbidity Index.
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in the cross-sectional UK CaHASE study (29), with the 
possible exception of lower numbers of dexamethasone 
users in our study. Taking this into account, our results 
can be assumed to be representative of the UK AD and 
CAH populations.
Our study has several strengths. We used a large 
population-based sample of patients of both sexes, 
across all adult age groups, with very strict inclusion 
and exclusion criteria, allowing us to include only pa-
tients with a true diagnosis of AD and CAH. Using the 
cohort study design allowed us to look at longitudinal 
occurrence of infections and antimicrobial use. There 
are also some limitations to our study. First, all data rely 
on the accurate recording of diagnoses by GPs and this 
could have resulted in some degree of misclassification 
of the exposed cohorts and of the different episodes of 
infection. Although GPs document reasons for consult-
ations in the electronic medical records, it is possible 
that when a patient presented with 2 or more condi-
tions, this may have not been accurately coded; how-
ever, all prescriptions are electronically documented 
and therefore are captured accurately. Second, the 
threshold for visiting GP might be lower in patients 
with PAI who receive regular education on the import-
ance of treating infections promptly to avoid adrenal 
crisis. This may be a factor resulting in a degree of over-
estimation of the difference in the infection rates we 
found between these cohorts. However, since patients 
with PAI are generally more medicalized, it is also pos-
sible that they own a higher knowledge of diseases and 
might decide to treat themselves without consulting 
the GP. Third, we could not evaluate the influence of 
different doses or types of glucocorticoid on the out-
comes of interest due to the methodology used and due 
to the small number of infection events when further 
subdividing our populations according to type of gluco-
corticoid. Furthermore, even though we tried to assess 
the impact of associated comorbidities by adjusting for 
Charlson Comorbidity Index, this does not exclude the 
possibility that some other confounders not accounted 
for in our analyses might have influenced our results. 
Last, although there is some evidence of an immune-
modulatory effect of androgens (30), we could not take 
this into account in our population as we had no data on 
dehydroepiandrosterone (DHEA) replacement therapy 
in AD patients, since this is a hospital-prescribed drug 
in the United Kingdom; similarly, we did not have data 
on biochemical control of androgen excess in the CAH 
patients.
Our findings have several practical implications. First, 
given the confirmation of a higher risk of infections in 
patients with PAI due to AD and CAH, all health care 
professionals involved in the care of PAI patients should 
have a heightened alertness for the possibility of infec-
tions in these patients. This may also provide a case for 
recommending a vaccination strategy in PAI (eg, against 
Streptococcus pneumoniae, the leading cause of LRTIs 
in adults) (31) to reduce the risk of these infections and 
related morbidity and mortality. Second, our paper pro-
vides additional evidence that nonphysiological delivery 
of glucocorticoid replacement by currently available pre-
parations represents a risk factor for the development of 
infections. This supports the case for a therapeutic shift 
toward more physiological replacement therapy op-
tions in these patients (32). Future studies will have to 
clarify whether achieving a more physiological delivery 
of glucocorticoid replacement will decrease the risk of 
infections in PAI, with the potential to result in reduced 
morbidity and mortality in these patients.
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